Global United States Continuous Glucose Monitoring Market Size, Share and Trends Analysis
The United States CGM market was valued at $3.8B in 2023, projected to reach $15.0B by 2032 at 16.5% CAGR.
$3.8B
$15.0B
16.5%
North America
Executive Summary
The U.S. continuous glucose monitoring market was valued at approximately USD 3.8 billion in 2023 and is projected to reach USD 15.0 billion by 2032, growing at a CAGR of 16.5%. Dominated by Dexcom and Abbott, the market is driven by rising diabetes prevalence, FDA approvals, and integration with insulin pumps. Real-time CGM leads adoption, with Type 1 diabetes patients representing the largest user segment. Expanding insurance coverage and wearable technology convergence present significant growth opportunities.
Key Highlights
U.S. CGM market projected to reach USD 15.0B by 2032 at 16.5% CAGR from USD 3.8B in 2023
Dexcom and Abbott collectively control over 75% of the U.S. CGM device market share
Consumer wellness CGM segment expected to grow fastest as non-diabetic users adopt glucose tracking
Market Overview
Market Context
The U.S. CGM market is in a high-growth phase driven by 37M+ diabetic patients, expanding PBM coverage, and next-generation sensor accuracy. Dexcom and Abbott lead, while closed-loop integration and consumer wellness expansion redefine competitive boundaries.
The U.S. CGM market is experiencing high growth fueled by over 37 million diabetics, increasing physician adoption, and next-gen sensor accuracy. Dexcom G7 and Abbott FreeStyle Libre 3 lead the competitive landscape with closed-loop integration reshaping treatment protocols.
Market Stage
High growth
Adoption Level
Growing
Key Trends
Market Forecast & Data
Base Year (2023)
$3.8B
Forecast (2032)
$15.0B
CAGR (2024-2032)
16.5%
| Year | Market size ($ Billion) |
|---|---|
| 2023Base year | $3.80B |
| 2024 | $4.43B |
| 2025 | $5.16B |
| 2026 | $6.01B |
| 2027 | $7.00B |
| 2028 | $8.15B |
| 2029 | $9.50B |
| 2030 | $11.07B |
| 2031 | $12.89B |
| 2032 | $15.02B |
Valued at USD 3.8B in 2023, the market is forecast to reach USD 15.0B by 2032 at 16.5% CAGR. Real-time CGM dominates at 65% share. Type 2 diabetes adoption and consumer wellness are the fastest-growing demand segments through 2032.
| Region | Market share | Growth rate | Largest market |
|---|---|---|---|
| North America | 42.0% | 16.8% | United States |
| Europe | 30.0% | 14.5% | Germany |
| Asia Pacific | 28.0% | 18.5% | China |
North America
#1Largest market: United States
Europe
#2Largest market: Germany
Market Dynamics
- Rising diabetes prevalence across all age groups in the U.S.
- FDA-cleared non-adjunctive use expanding patient eligibility
- Payer coverage expansion by major U.S. PBMs
Market Segmentation
| Segment | Share |
|---|---|
| Real-Time CGMDominant segment providing continuous glucose readings with real-time alerts and smartphone connectivity. | 65.0% |
| Flash CGMScan-based systems offering on-demand glucose readings without continuous data transmission. | 35.0% |
| Total | 100.0% |
| Segment | Share |
|---|---|
| Type 1 DiabetesLargest application segment driven by insulin-dependent patients requiring constant glucose monitoring. | 55.0% |
| Type 2 DiabetesFastest-growing segment as CGM adoption expands beyond insulin-dependent populations. | 35.0% |
| OthersIncludes gestational diabetes, prediabetes, and consumer wellness applications. | 10.0% |
| Total | 100.0% |
By End User
- Hospitals
- Home Care Settings
- Diabetes Clinics
Regional Analysis
North America
Lead: United StatesLargest market driven by high diabetes prevalence, advanced healthcare infrastructure, and strong insurance coverage.
Europe
Lead: GermanyGrowing adoption supported by national healthcare reimbursement and rising Type 2 diabetes cases.
Asia Pacific
Lead: ChinaHighest growth region due to expanding diabetic population and increasing healthcare expenditure.
Country-Level Analysis
| Country | Share | Growth |
|---|---|---|
| United States | 42.0% | +16.8% |
| Germany | 14.0% | +14.2% |
| China | 12.0% | +19.5% |
Competitive Landscape
Dexcom, Inc.
United States
Dominates U.S. CGM with G7 system; all major PBMs provide coverage reaching 6M+ eligible patients.
U.S.-based market leader in CGM technology known for the G7 real-time system with factory calibration and 15-day sensor wear.
Abbott Laboratories
United States
FreeStyle Libre franchise targets $10B in sales by 2028; Lingo CGM expands into consumer wellness segment.
Global healthcare company with the FreeStyle Libre franchise targeting USD 10B in franchise sales by 2028 and expanding into consumer wellness.
Medtronic plc
Ireland
MiniMed 780G with Simplera Sync sensor offers integrated closed-loop insulin delivery system.
Ireland-headquartered medtech giant offering integrated closed-loop insulin delivery with the MiniMed 780G and Simplera Sync sensor.
Recent Developments
Expanded coverage through all three major U.S. PBMs reaching over 6 million eligible patients
Launched Lingo CGM for consumer wellness market targeting non-diabetic users
Regulatory Landscape
Research Methodology
Primary research
- Expert interviews
- Surveys
Secondary research
- Industry reports
- Company financials
Validation: Triangulation method
Strategic Takeaways
The 16.5% CAGR through 2032 signals strong ROI potential in CGM device and consumable portfolios.
Differentiation through AI-driven analytics and closed-loop integration will define market leadership.
Expanding CGM coverage improves outcomes and reduces long-term diabetes complication costs.
CGM adoption is becoming standard of care across both Type 1 and insulin-naive Type 2 populations.
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- Medical DevicesGlobal North America Continuous Glucose Monitoring Market$9.5B · 16% CAGR
- Medical DevicesGlobal Continuous Glucose Monitoring Market$9.8B · 15.8% CAGR
- Medical DevicesGlobal Asia Pacific Continuous Glucose Monitoring Market$10.0B · 20.9% CAGR
- Medical DevicesGlobal Europe Continuous Glucose Monitoring Market$10.0B · 19.6% CAGR
- Medical DevicesUnited States Surgical Robotics Market$6.9B · 8.8% CAGR
- Medical DevicesGlobal United States Wearable Medical Devices Market$38.5B · 15.4% CAGR